Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia Maria, 1981-
  • Barallobre, María José
  • Di Vona, Chiara, 1981-
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera, Mariona
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Luna Gargantilla, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis., This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), “La Marató de TV3” to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European CommissionFP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Skłodowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011-045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011-11140), and A.F.F. is a Marie Skłodowska-Curie ESR fellow.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr
  • Sabata, Helena
  • Vilalta, Odena
  • Gouveia, Leonor
  • Angulo-Urarte, Ana
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo, Lucía
  • Esteve-Codina, Anna
  • Lavarino, Cinzia
  • Javierre, Biola M.
  • Celis-Passini, Veronica Paola
  • Rovira, Carlota
  • López-Fernández, Susana
  • Baselga, Eulàlia
  • Mora, Jaume
  • Castillo, Sandra D.
  • Graupera, Mariona
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations., The research leading to these results has received funding by the Spanish Ministry of Science and Innovation MICINN (PID2020-116184RB-I00 /AEI/10.13038/501100011033). M.G. laboratory is supported by the research grants SAF2017-89116R-P (FEDER/EU) from MCIU (Spain) co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe and PID2020-116184RB-I00 from MCEI; PTEN RESEARCH Foundation (IJC-21-001); la Caixa Banking Foundation (LCF/PR/PR16/51110035 and LCF/PR/HR19/52160023; also to E.B. and J.M.); by la Asociación Española contra el Cancer (AECC)-Grupos Traslacionales (GCTRA18006CARR); by la Fundación BBVA (Ayuda Fundación BBVA a Equipos de Investigación Científica 2019); World Cancer Research (21-0159). The computations and data handling were enabled by resources in projects SNIC 2019/30-26 and SNIC 2019/8-129, provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Personal support was from Marie-Curie ITN Actions (P.K. and J.Z.) grant agreement 675392. L.G. is funded by the Swedish Research Council (2018-06591). S.D.C. is a recipient of a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 749731. S.D.C. is currently funded by la Caixa Banking Foundation Junior Leader project (LCF/BQ/PR20/11770002). E.B. is funded by the Agencia Estatal de Investigación (Proyectos de investigación en salud PI20/00102).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  • Palafox, Marta
  • González-Pérez, Abel
  • Arribas, Joaquín
  • López Bigas, Núria
  • Serra, Violeta
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies., This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540) [to V.S.]. V.S. received funds from the Instituto de Salud Carlos III: grants PI13/01714, CP14/00228, MV15/00041, CPII19/00033 and PI20/00892. M.P. received a Juan de la Cierva Grant from the Ministerio de Economía y Competitividad (FJCI-2015-25412), L.Mo. a grant from FI-AGAUR (2019 FI_B 01199), F.B-M. a grant from the Fundación Científica Asociación Española Contra el Cáncer (AECC_Postdoctoral17-1062) and M.S-G, a Marie Slodowska-Curie Innovative Training Networks PhD fellowship (H2020-MSCA-ITN-2015_675392). This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181) and Asociación Española Contra el Cáncer (to J.A.). R.B.C. laboratory is supported by Breast Cancer Now (grant numbers: MAN-Q1 and MAN-Q2), NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007) and EdiREX Horizon 2020 grant No.731105. The xenograft program in the C.C. laboratory is supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). This work has been supported by NIH grants P30 CA008748 and RO1CA190642-01, the CDMRP grant BC171535P1, and the Breast Cancer Research Foundation [to M.S.]. A.P. received funds from Instituto de Salud Carlos III—PI16/00904 and PI19/01846, Breast Cancer Now—2018NOVPCC1294, Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research 19-20-26-PRAT, Fundació La Marató TV3 201935-30, the European Union’s Horizon 2020 research and innovation program H2020-SC1-BHC-2018-2020. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). C. S. Verma reports grants from MSD International and grants from Ipsen outside the submitted work.
Repisalud
Publication Artículo científico (JournalArticle)

Angiocrine polyamine production regulates adiposity.

  • Monelli, Erika
  • Villacampa, Pilar
  • Zabala-Letona, Amaia
  • Martinez-Romero, Anabel
  • Llena, Judith
  • Beiroa, Daniel
  • Gouveia, Leonor
  • Chivite, Iñigo
  • Zagmutt, Sebastián
  • Gama-Perez, Pau
  • Osorio-Conles, Oscar
  • Muixi, Laia
  • Martinez-Gonzalez, Ainara
  • Castillo, Sandra D
  • Martín-Martín, Natalia
  • Castel, Pau
  • Valcarcel-Jimenez, Lorea
  • Garcia-Gonzalez, Irene
  • Villena, Josep A
  • Fernandez-Ruiz, Sonia
  • Serra, Dolors
  • Herrero, Laura
  • Benedito, Rui
  • Garcia-Roves, Pablo
  • Vidal, Josep
  • Cohen, Paul
  • Nogueiras, Rubén
  • Claret, Marc
  • Carracedo, Arkaitz
  • Graupera, Mariona
Reciprocal interactions between endothelial cells (ECs) and adipocytes are fundamental to maintain white adipose tissue (WAT) homeostasis, as illustrated by the activation of angiogenesis upon WAT expansion, a process that is impaired in obesity. However, the molecular mechanisms underlying the crosstalk between ECs and adipocytes remain poorly understood. Here, we show that local production of polyamines in ECs stimulates adipocyte lipolysis and regulates WAT homeostasis in mice. We promote enhanced cell-autonomous angiogenesis by deleting Pten in the murine endothelium. Endothelial Pten loss leads to a WAT-selective phenotype, characterized by reduced body weight and adiposity in pathophysiological conditions. This phenotype stems from enhanced fatty acid β-oxidation in ECs concomitant with a paracrine lipolytic action on adipocytes, accounting for reduced adiposity. Combined analysis of murine models, isolated ECs and human specimens reveals that WAT lipolysis is mediated by mTORC1-dependent production of polyamines by ECs. Our results indicate that angiocrine metabolic signals are important for WAT homeostasis and organismal metabolism.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

  • Angulo Urarte, Ana
  • Casado, Pedro
  • Castillo, Sandra D.
  • Kobialka, Piotr
  • Kotini, Maria Paraskevi
  • Figueiredo, Ana Raquel Martins
  • Castel Morales, Pau
  • Rajeeve, Vinothini
  • Milà Guasch, Maria
  • Millán, Jaime
  • Wiesner, Cora
  • Serra, Helena
  • Muixi, Laura
  • Casanovas i Casanovas, Oriol
  • Viñals Canals, Francesc
  • Affolter, Markus
  • Gerhardt, Holger
  • Huveneers, Stephan
  • Belting, Heinz-Georg
  • Cutillas, Pedro R.
  • Graupera i Garcia-Milà, Mariona
Angiogenesis is a dynamic process relying on endothelial cell rearrangements within vascular tubes, yet the underlying mechanisms and functional relevance are poorly understood. Here we show that PI3Kα regulates endothelial cell rearrangements using a combination of a PI3Kα-selective inhibitor and endothelial-specific genetic deletion to abrogate PI3Kα activity during vessel development. Quantitative phosphoproteomics together with detailed cell biology analyses in vivo and in vitro reveal that PI3K signalling prevents NUAK1-dependent phosphorylation of the myosin phosphatase targeting-1 (MYPT1) protein, thereby allowing myosin light chain phosphatase (MLCP) activity and ultimately downregulating actomyosin contractility. Decreased PI3K activity enhances actomyosin contractility and impairs junctional remodelling and stabilization. This leads to overstretched endothelial cells that fail to anastomose properly and form aberrant superimposed layers within the vasculature. Our findings define the PI3K/NUAK1/MYPT1/MLCP axis as a critical pathway to regulate actomyosin contractility in endothelial cells, supporting vascular patterning and expansion through the control of cell rearrangement.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia
  • Barallobre, María José
  • Di Vona, Chiara
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna Cornadó, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera i Garcia-Milà, Mariona
  • Valverde, Miguel Ángel
  • Luna, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLC gamma 1 activation. Notably, Dyrk1 alpha heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/C-a2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

  • Bohnacker, Thomas
  • Díaz, José Fernando
  • Wymann, Matthias P.
13 p.-7 fig. Bohnacker, Thomas et al., BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization. Here, we developed two chemical derivatives that differ from BKM120 by only one atom.We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors. Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs. Our results raise concerns over BKM120’s generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies., This work was supported by the Swiss Commission for Technology and Innovation (CTI) by PFLS-LS grants 14032.1,15811.2 and 17241.1; the Stiftung für Krebsbekämpfung grant 341, Swiss National Science Foundation grants 310030_153211 and 316030_133860 (to M.P.W.), and 310030B_138659 and 31003A_166608 (to M.O.S.); in part by European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 675392, and grants BIO2013-42984-R (Ministerio de Economia y Competitividad), S2010/BMD-2457 BIPEDD2 (Comunidad Autónoma de Madrid) to J.F.D.; and by the MRC to R.L.W. (U105184308, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia
  • Barallobre, María-José
  • Di Vona, Chiara
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat, Cristina
  • Arbones, Maria L.
  • Graupera, Mariona
  • Valverde, Miguel A.
  • Luna, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis, This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), ‘‘La Marato´ de TV3’’ to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European Commission FP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Sk1odowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011- 045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011- 11140), and A.F.F. is a Marie Sk1odowska-Curie ESR fellow. We acknowledge the support of the MINECO Centro de Excelencia Severo Ochoa and María de Maeztu Programme and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia Maria, 1981-
  • Barallobre, María José
  • Di Vona, Chiara, 1981-
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera, Mariona
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Luna Gargantilla, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis., This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), “La Marató de TV3” to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European CommissionFP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Skłodowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011-045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011-11140), and A.F.F. is a Marie Skłodowska-Curie ESR fellow.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  • Palafox, Marta
  • González-Pérez, Abel
  • Arribas, Joaquín
  • López Bigas, Núria
  • Serra, Violeta
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies., This study has been supported by the Susan G. Komen Foundation (CCR15330331) and by the Catalan Agency AGAUR (2017 SGR 540) [to V.S.]. V.S. received funds from the Instituto de Salud Carlos III: grants PI13/01714, CP14/00228, MV15/00041, CPII19/00033 and PI20/00892. M.P. received a Juan de la Cierva Grant from the Ministerio de Economía y Competitividad (FJCI-2015-25412), L.Mo. a grant from FI-AGAUR (2019 FI_B 01199), F.B-M. a grant from the Fundación Científica Asociación Española Contra el Cáncer (AECC_Postdoctoral17-1062) and M.S-G, a Marie Slodowska-Curie Innovative Training Networks PhD fellowship (H2020-MSCA-ITN-2015_675392). This work was supported by Breast Cancer Research Foundation (BCRF-19-08), Instituto de Salud Carlos III Project Reference number AC15/00062 and the EC under the framework of the ERA-NET TRANSCAN-2 initiative co-financed by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181) and Asociación Española Contra el Cáncer (to J.A.). R.B.C. laboratory is supported by Breast Cancer Now (grant numbers: MAN-Q1 and MAN-Q2), NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007) and EdiREX Horizon 2020 grant No.731105. The xenograft program in the C.C. laboratory is supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN). This work has been supported by NIH grants P30 CA008748 and RO1CA190642-01, the CDMRP grant BC171535P1, and the Breast Cancer Research Foundation [to M.S.]. A.P. received funds from Instituto de Salud Carlos III—PI16/00904 and PI19/01846, Breast Cancer Now—2018NOVPCC1294, Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research 19-20-26-PRAT, Fundació La Marató TV3 201935-30, the European Union’s Horizon 2020 research and innovation program H2020-SC1-BHC-2018-2020. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). C. S. Verma reports grants from MSD International and grants from Ipsen outside the submitted work.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr
  • Sabata, Helena
  • Vilalta, Odena
  • Gouveia, Leonor
  • Angulo-Urarte, Ana
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo, Lucía
  • Esteve-Codina, Anna
  • Lavarino, Cinzia
  • Javierre, Biola M.
  • Celis-Passini, Veronica Paola
  • Rovira, Carlota
  • López-Fernández, Susana
  • Baselga, Eulàlia
  • Mora, Jaume
  • Castillo, Sandra D.
  • Graupera, Mariona
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations., The research leading to these results has received funding by the Spanish Ministry of Science and Innovation MICINN (PID2020-116184RB-I00 /AEI/10.13038/501100011033). M.G. laboratory is supported by the research grants SAF2017-89116R-P (FEDER/EU) from MCIU (Spain) co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe and PID2020-116184RB-I00 from MCEI; PTEN RESEARCH Foundation (IJC-21-001); la Caixa Banking Foundation (LCF/PR/PR16/51110035 and LCF/PR/HR19/52160023; also to E.B. and J.M.); by la Asociación Española contra el Cancer (AECC)-Grupos Traslacionales (GCTRA18006CARR); by la Fundación BBVA (Ayuda Fundación BBVA a Equipos de Investigación Científica 2019); World Cancer Research (21-0159). The computations and data handling were enabled by resources in projects SNIC 2019/30-26 and SNIC 2019/8-129, provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Personal support was from Marie-Curie ITN Actions (P.K. and J.Z.) grant agreement 675392. L.G. is funded by the Swedish Research Council (2018-06591). S.D.C. is a recipient of a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 749731. S.D.C. is currently funded by la Caixa Banking Foundation Junior Leader project (LCF/BQ/PR20/11770002). E.B. is funded by the Agencia Estatal de Investigación (Proyectos de investigación en salud PI20/00102).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

  • Angulo Urarte, Ana
  • Casado, Pedro
  • Castillo, Sandra D.
  • Kobialka, Piotr
  • Kotini, Maria Paraskevi
  • Figueiredo, Ana Raquel Martins
  • Castel Morales, Pau
  • Rajeeve, Vinothini
  • Milà Guasch, Maria
  • Millán, Jaime
  • Wiesner, Cora
  • Serra, Helena
  • Muixi, Laura
  • Casanovas i Casanovas, Oriol
  • Viñals Canals, Francesc
  • Affolter, Markus
  • Gerhardt, Holger
  • Huveneers, Stephan
  • Belting, Heinz-Georg
  • Cutillas, Pedro R.
  • Graupera i Garcia-Milà, Mariona
Angiogenesis is a dynamic process relying on endothelial cell rearrangements within vascular tubes, yet the underlying mechanisms and functional relevance are poorly understood. Here we show that PI3Kα regulates endothelial cell rearrangements using a combination of a PI3Kα-selective inhibitor and endothelial-specific genetic deletion to abrogate PI3Kα activity during vessel development. Quantitative phosphoproteomics together with detailed cell biology analyses in vivo and in vitro reveal that PI3K signalling prevents NUAK1-dependent phosphorylation of the myosin phosphatase targeting-1 (MYPT1) protein, thereby allowing myosin light chain phosphatase (MLCP) activity and ultimately downregulating actomyosin contractility. Decreased PI3K activity enhances actomyosin contractility and impairs junctional remodelling and stabilization. This leads to overstretched endothelial cells that fail to anastomose properly and form aberrant superimposed layers within the vasculature. Our findings define the PI3K/NUAK1/MYPT1/MLCP axis as a critical pathway to regulate actomyosin contractility in endothelial cells, supporting vascular patterning and expansion through the control of cell rearrangement.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia
  • Barallobre, María José
  • Di Vona, Chiara
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna Cornadó, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera i Garcia-Milà, Mariona
  • Valverde, Miguel Ángel
  • Luna, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLC gamma 1 activation. Notably, Dyrk1 alpha heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/C-a2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr|||0000-0003-4765-168X
  • Sabata Perez, Helena|||0000-0003-0637-0638
  • Vilalta, Odena
  • Gouveia, Leonor|||0000-0002-3825-8571
  • Angulo-Urarte, Ana|||0000-0002-8024-814X
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo-Escudero, Lucía|||0000-0002-8364-9520
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Lavarino, Cinzia
  • Javierre, B. M.|||0000-0002-8682-6748
  • Celis, Verónica Paola
  • Rovira, Cinzia
  • López-Fernández, Susana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Mora, J.
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3ca activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations.